View Article

  • Clinical Pharmacist-Led Antibiotic Stewardship Programs: A Key Strategy for Healthy India-a comprehensive review

  • Department of pharmacy practice, Shivlingeshwar college of pharmacy Almala, dist. Latur-413512.

Abstract

Antimicrobial resistance (AMR) is identified as one of the most threatening challenges to global public health in the 21st century. The efficacy of modern medicine is threatened by the misuse and overuse of antibiotics, as warned by the World Health Organization on several occasions. The number of reported multidrug-resistant (MDR) infections is rising in India, which is one of the biggest users of antibiotics globally, due to improper use and a lack of compliance with regulations. Antibiotic Stewardship Programs (ASPs) are systematic strategies that aim to promote the rational use of antibiotics, enhance patient outcomes, decrease resistance, and save medical expenses. Clinical pharmacists are increasingly identified as important leaders in the execution of ASP due to their knowledge in pharmacotherapy, pharmacokinetics, and evidence-based medicine. The effects of AMR in India and globally, the aims, and the structure of ASPs, the growing role of clinical pharmacists, summary of evidence, policies, and strategies to implement the “Healthy India” campaign will be covered in this review. It is important to enhance pharmacist-led stewardship to ensure the long-term efficacy of antibiotics. This review will cover the magnitude of antimicrobial resistance (AMR) in India and the world at large, the aims and structure of ASPs, the growing role of clinical pharmacists, a summary of the evidence, and strategies that will help in achieving the “Healthy India” initiative. Enhancing stewardship by pharmacists is required to ensure the long-term success of public health initiatives.

Keywords

Antibiotic Stewardship, antimicrobial Stewardship program, antimicrobial resistance, Healthy India, Patient safety

Introduction

× Popup Image

The death rate due to infectious diseases has been reduced to a large extent by antibiotics [32]. However, the emergence of AMR is a threat to these achievements [1,2]. AMR has been declared a global health crisis by the World Health Organization [1]. India has a high rate of antibiotic consumption and infectious diseases [8,9]. The problem of resistance is worsened by the method of empirical prescribing and over-the-counter distribution [24, 25]. The aim of the country’s programs such as Ayushman Bharat is to enhance the infrastructure of public health [30]. To promote the judicious use of antibiotics, pharmacist-led programs are important [14,15]. One of the biggest successes of the 20th century is the discovery of antibiotics, which have transformed what was a life-threatening infection into a treatable disease and have enabled the performance of complex medical procedures such as organ transplants, chemotherapy, and surgery. However, the success of antimicrobial treatment has been jeopardized by the emergence of antimicrobial resistance (AMR). The World Health Organization has listed AMR as one of the top ten global health threats to humanity and has forecast that the world is on its way to a “post-antibiotic era” where common infections will once again become life-threatening [34,35].

Antimicrobial resistance can be described as the emergence of microorganisms such as bacteria, viruses, fungi, and parasites that are resistant to the drugs used to treat infections. Although antimicrobial resistance is a natural phenomenon, it is accelerated by the misuse and overuse of antimicrobial drugs in human and veterinary medicine and agriculture [36,37]. Globally, antimicrobial resistance has been associated with longer hospital stays, healthcare costs, treatment failure, and deaths [38,39]. Economic models have forecasted that if AMR is not controlled, there will be millions of deaths per year and economic losses by 2050 [36].

Data from the Indian Council of Medical Research shows an increase in the resistance rates of Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii [40]. Likewise, the work of the National Centre for Disease Control shows the increasing number of multidrug-resistant organisms in both tertiary and secondary care hospitals [41]. Carbapenem resistance and the rise of extended-spectrum beta-lactamases (ESBL) are some of the alarming trends in Indian hospitals [40, 42].

Realizing the gravity of the situation, India has taken steps to control the situation through Schedule H1, which regulates the over-the-counter sale of certain antibiotics [43]. Moreover, the Government of India has developed the National Action Plan on AMR (NAP-AMR), which aligns with the WHO Global Action Plan, which aims at the surveillance of antimicrobial resistance, prudent use of antimicrobials, infection control, and research [34, 44]. Changes in the public health sector, such as Ayushman Bharat, provide opportunities to incorporate Antimicrobial Stewardship Programs as a component of the health care delivery system [45].

2.  ANTIMICROBIAL RESISTANCE (AMR): THE RISING THREAT.

2.1 Global prospective

An International View According to the World Health Organization, if left unchecked, AMR could result in 10 million deaths per year by 2050. Serious medical problems are caused by drug-resistant bacteria such as drug-resistant TB, carbapenem-resistant Enterobacteriaceae (CRE), and MRSA. It is estimated that AMR could result in trillions of dollars in economic losses worldwide due to higher hospitalization and medical expenses.

2.2 Indian Scenario

India is one of the largest users of antibiotics. The Indian Council of Medical Research's surveillance shows that the Acinetobacter species, Klebsiella pneumoniae, and E. coli are becoming increasingly resistant. MDR bacteria are also prevalent in tertiary care hospitals, as reported by the National Centre for Disease Control. Abuse has been fuelled by the easy availability of antibiotics over-the-counter without a prescription, especially prior to the introduction of Schedule H1.

2.3 Reasons for Abuse of Antibiotics

 Self-medication Unsuitable empirical treatment Unfinished classes Poor enforcement of regulations Misuse in veterinary and agricultural settings.

3. PROGRAMS FOR ANTIBIOTIC STEWARDSHIP (ASP)

3.1 Definition

ASPs are organized approaches to promote optimal drug selection, dosage, route, and duration to optimize and monitor appropriate antibiotic use.

 3.2 Fundamental ASP Components

The Centres for Disease Control and Prevention state that the fundamental components are:

•  Leadership

•  Dedication

•  Responsibility

•  Knowledge of drugs (clinical pharmacist)

•  Monitoring Action

•  Learning

3.3 ASP's Objectives

•  Improve patient health care

•  Lower the number of adverse medication reactions

•  Lower health care costs

•  Lower resistance

4. CLINICAL PHARMACIST AS LEADERS IN ASP GOVENANCE

Apart from their traditional roles, clinical pharmacists in ASP have leadership roles as:

  • Antimicrobial policy developers
  • Drug use reviewers
  • Resistance pattern analysts
  • Hospital antibiogram organizers
  • Medication safety managers
  • Educators and trainers

Their pharmacological expertise helps them optimize:

  • Pharmacokinetics (PK)
  • Pharmacodynamics (PD)
  • Drug interactions
  • Dose adjustments in renal/hepatic impairment
  • Adverse drug reaction monitoring

In Indian tertiary care hospitals, where infectious disease specialists are less in number, clinical pharmacists have a pivotal role as antimicrobial specialists.

 

5. ADVANCED STEWARDSHIP STRATEGIES LED BY PHARMACIST

5.1 Antimicrobial Time-Out

Review at 48-72 hours post-antibiotic therapy to reassess:

  • Continuation of therapy
  • Culture and sensitivity reports
  • De-escalation therapy

5.2 Restriction and Preauthorization Policies

Highly restricted antibiotics such as:

  • Carbapenems
  • Colistin
  • Linezolid
  • Tigecycline

require approval from pharmacists for dispensing.

5.3 Rapid Diagnostic Integration

Pharmacists collaborate with microbiology labs to analyse:

  • MALDI-TOF results
  • PCR-based resistance patterns
  • Blood culture sensitivity reports

This helps in early targeted therapy.

5.4 IV-to-Oral Conversion Protocols

Clinical pharmacists develop hospital protocols for safe conversion, thus reducing:

  • Hospital stay
  • IV catheter-related complications
  • Treatment costs

6. ROLE IN SPECIAL POPULATION

6.1 Pediatrics

  • Weight-based dosing
  • Neonatal sepsis protocols
  • Prevention of antibiotic toxicity

6.2 Geriatrics

  • Polypharmacy management
  • Renal dose adjustments
  • Avoidance of nephrotoxic combinations

6.3 Critical Care

TDM for vancomycin and aminogly.

7. COMMUNITY PHARMACY-BASED STEWARDSHIP

India has a large number of community pharmacies. Extending stewardship to this level involves:

  • Educating patients on finishing antibiotic courses
  • Refusing over-the-counter sales of antibiotics
  • Promoting alternatives for symptomatic treatment
  • Reporting unusual trends in antibiotic sales

Community pharmacists can serve as gatekeepers against misuse.

8. MEASURABLE INDICATORS FOR ANTIBIOTIC STEWARDSHIP PROGRAM (ASP) SUCESS

The evaluation of an Antibiotic Stewardship Program (ASP) is essential to determine whether stewardship interventions are producing meaningful improvements in antibiotic use, patient safety, resistance control, and healthcare costs. Measurable indicators provide objective data that allow hospitals and healthcare systems to monitor progress, justify resource allocation, and continuously refine stewardship strategies. These indicators should be standardized, reproducible, and aligned with institutional and national antimicrobial resistance (AMR) goals.A comprehensive assessment of ASP success generally focuses on four broad domains: antibiotic utilization, clinical outcomes, microbiological impact, and economic performance.

8.1. Antibiotic Utilization Indicators

Monitoring antibiotic consumption is a primary indicator of stewardship effectiveness. It reflects prescribing behaviour and helps identify trends in antimicrobial exposure.One of the most widely accepted metrics is Defined Daily Dose (DDD) per 100 bed-days, which standardizes antibiotic use for comparison across institutions and time periods.This indicator allows hospitals to evaluate whether stewardship interventions, such as formulary restrictions or prescription audits, are reducing unnecessary antibiotic use.Another important metric is Days of Therapy (DOT) per 1000 patient-days, which counts the number of days a patient receives a specific antibiotic regardless of dose. DOT is particularly useful in pediatric and critical care settings where dosing may vary.Reduction in broad-spectrum antibiotic utilization, increased IV-to-oral switch rates, and improved documentation of indication and duration are also measurable markers of rational prescribing.Sustained reduction in inappropriate empirical therapy without compromising patient safety is a strong signal of ASP success.

8.2. Clinical Outcome Indicators

Clinical outcomes can be used to measure the success of stewardship activities in enhancing patient care. While a decrease in antibiotic use is a desirable outcome, it should not be achieved at the cost of treatment efficacy.

  • The most critical clinical outcome indicators are as follows:
  • Rates of infection-related mortality
  • Hospital length of stay (LOS)
  • 30-day readmission rates for infectious diagnoses
  • Incidence of adverse drug reactions related to antibiotics
  • Incidence of Clostridioides difficile infection

A successful ASP should ideally observe no change or a decrease in mortality and readmission rates, as well as a decrease in unnecessary exposure to antibiotics. A reduced LOS is a good measure of the success of de-escalation and optimization of therapy.Monitoring of adverse drug events is also a point to be considered, as optimized antibiotic therapy prevents nephrotoxicity, hepatotoxicity, and drug interactions.

8.3. Microbiological Indicators

The end result of good stewardship is the deceleration of antimicrobial resistance. Thus, microbiological trends are important indicators of the long-term success of ASP strategies.

The antibiogram is monitored annually by the hospital to identify the susceptibility trends of the dominant microbes. A decrease in the sensitivity rates to first-line antibiotics indicates a decrease in the selective pressure exerted by the overuse of broad-spectrum antibiotics.A decrease in the rate of MDROs, such as carbapenem-resistant Enterobacter ales or methicillin-resistant Staphylococcus aureus, indicates a positive impact of good stewardship strategies.However, the trends of resistance rates may not be easily identifiable and thus need close monitoring to enable correct interpretation.

8.4. Economic Indicators

Cost analysis is very useful in a resource-limited healthcare environment. ASPs are not only useful but also cost-effective.

The important economic indicators are:

  • Total cost of antibiotic procurement
  • Cost per treated infection episode
  • Reduction in use of high-cost reserve antibiotics
  • Reduction in ICU costs due to reduced stay

Cost savings should be interpreted in the context of clinical outcomes to ensure that cost savings do not negatively impact patient care.

8.5. Quality and Compliance Indicators

Quality indicators measure the variability of program implementation. These include:

  • Percentage of prescriptions reviewed by the stewardship team
  • Adherence to hospital antibiotic stewardship guidelines
  • Documentation of antimicrobial use
  • Culture sampling prior to antibiotic administration
  • De-escalation in 48-72 hours post culture results

Regular audits and feedback can help improve accountability and adherence to appropriate prescribing practices.

8.6. Role of Integrated Monitoring

It is impossible to quantify the success of ASP with a single criterion. A properly integrated analysis of utilization, outcomes, resistance, and economic studies will give a comprehensive analysis.

Continuous monitoring will help the healthcare organization to:

  • Detect the emergence of resistance patterns
  • Modify the guidelines for empirical treatment
  • Enhance training programs
  • Determine the role of interventions performed by clinical pharmacists

9. ROLE OF CLINICAL PHARMACIST IN ANTIBIOTIC STEWARDSHIP

Clinical Pharmacists' Contribution to Antibiotic Stewardship Because of their pharmacological expertise, clinical pharmacists have a unique position to direct ASP initiatives.

 9.1 Prospective Evaluation and Input To improve compliance with guidelines

clinical pharmacists examine antibiotic prescriptions and provide prescribers with immediate feedback.

 9.2 PK/PD Monitoring and Dose Optimization

Safety and efficacy are improved by individualized dose adjustment according to renal impairment and therapeutic drug monitoring.

9.3 Antibiotic Guidelines Development

Together with microbiology labs, pharmacists help develop hospital antibiograms.

 

 9.4 Therapy De-escalation and Streamlining

Resistance pressure is decreased by switching from broad-spectrum to narrow-spectrum antibiotics according to culture results.

 9.5 Awareness and Education

Antibiotic awareness and compliance are improved by patient education and healthcare worker training.

9.6 collaboration with health care team

Cooperation with the Medical Staff Multidisciplinary efforts are improved by participation in infection control committees.

10. EVIDENCE SUPPORTING PHARMACIST- LED ASP

10.1 Medical Results

 Reductions in readmissions, hospitalization, and mortality were observed in studies involving pharmacist-led ASPs.

10.2 The Effect on the Economy

 There was a marked cost savings due to reduced inappropriate use and enhanced antibiotic procurement.

10.3 Resistance Reduction

 Resistance Reduction observed a reduction in MDR and an improvement in trends for antibiotic sensitivity.

10.4 Research on India

 Adherence and carbapenem use were reduced in Indian tertiary centres with pharmacist-led ASPs.

11. INDIA’S NATIONAL POLICIES AND REGULATORY STRUCTURE

 India developed the National Action Plan on AMR (NAP-AMR) based on the WHO's Global Action Plan.

 Key organizations involved are:

 • National Centre for Disease Control

 • Indian Council of Medical Research

 Sales of over-the-counter antibiotics are regulated by laws such as Schedule H1.

12. ISSUES IN THE IMPLEMENTATION OF ASP IN INDIA

•      India Lack of clinical pharmacists with trainings

•      inadequate infrastructure 

•      Diagnostic limitations

•      Resistance from prescribers

•      Issues in policy implementation

13. STRATEGIES FOR IMPROVING ASP IMPLEMENTATION BY PHARMACIST

•      Expansion of Pharm.D. programs

•      ASP is mandatory for NABH accreditation.

•      Audit of electronic prescriptions

•      Tele pharmacy services

•      Improved monitoring systems

14. IMPACT ON VISION ON HEALTHY

India Successful ASP implementation contributes to:

•  Reduced infections

•  Antibiotic efficacy for long periods 

•  Lower healthcare costs

•  Attainment of SDG 3 (Good Health and Well-Being).

15. SUGGESTIONS

•  Enforcement and policies regarding OTC

•  Mandates of the Institutional ASP

•  Changes in the curriculum of pharmacy education

•  Campaigns for community awareness

CONCLUSION

The economic and health conditions of India are threatened by AMR. A successful and evidence-based strategy for maximizing antibiotic use, reducing resistance, and improving outcomes can be provided by ASPs conducted by pharmacists. To have a healthy India, collaboration, enforcement, and development are the keys.

REFERENCES

  1. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
  2. WHO. Antimicrobial resistance global report. Geneva: WHO; 2023.
  3. O’Neill J. Review on antimicrobial resistance. London; 2016.
  4. CDC. Core elements of hospital antibiotic stewardship programs. Atlanta; 2019.
  5. ICMR. Antimicrobial resistance surveillance report. New Delhi; 2022.
  6. NCDC. National programme on AMR containment. Delhi; 2021.
  7. Government of India. National Action Plan on AMR 2017–2021.
  8. Laxminarayan R, et al. Antibiotic resistance in India. Lancet Infect Dis. 2013.
  9. Klein EY, et al. Global antibiotic consumption. PNAS. 2018.
  10. Davey P, et al. Interventions to improve antibiotic prescribing. Cochrane Database. 2017.
  11. Dyar OJ, et al. What is antimicrobial stewardship? Clin Microbiol Infect. 2017.
  12. Dellit TH, et al. IDSA guidelines for ASP. Clin Infect Dis. 2007.
  13. Barlam TF, et al. Implementing ASP. Clin Infect Dis. 2016.
  14. Pulcini C, et al. Role of pharmacists in stewardship. Int J Antimicrobe Agents. 2014.
  15. MacDougall C, Polk RE. Stewardship programs. Clin Microbiol Rev. 2005.
  16. Schuts EC, et al. Current evidence for ASP. Lancet Infect Dis. 2016.
  17. Nathwani D, et al. Impact of stewardship. J Antimicrob Chemother. 2019.
  18. WHO. GLASS report. Geneva; 2022.
  19. Tamma PD, et al. Stewardship strategies. Clin Infect Dis. 2014.
  20. Dik JW, et al. Measuring antibiotic use. Lancet Infect Dis. 2016.
  21. Charani E, et al. Behavioral change in stewardship. Clin Infect Dis. 2013.
  22. ICMR. Treatment guidelines for antimicrobial use. 2019.
  23. Ministry of Health India. Schedule H1 notification. 2014.
  24. Kotwani A, et al. Antibiotic use in India. BMJ Glob Health. 2019.
  25. Chandy SJ, et al. Community antibiotic use. Indian J Med Res. 2013.
  26. WHO. Antimicrobial stewardship programmes in healthcare facilities. 2019.
  27. CDC. Antibiotic resistance threats report. 2019.
  28. Nair M, et al. Hospital antibiotic policy India. J Clin Diagn Res. 2017.
  29. Singh S, et al. ASP implementation India. Indian J Pharm Pract. 2020.
  30. Ayushman Bharat PMJAY guidelines. Govt of India. 2022.
  31. OECD. Stemming the superbug tide. 2018.
  32. Holmes AH, et al. Understanding drivers of AMR. Lancet. 2016.
  33. Llor C, Bjerrum L. Antimicrobial prescribing. Clin Microbiol Infect. 2014.
  34. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
  35. World Health Organization. Antimicrobial resistance global report. Geneva: WHO; 2023.
  36. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London; 2016.
  37. Holmes AH, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–87.
  38. Schuts EC, et al. Current evidence on hospital antimicrobial stewardship objectives. Lancet Infect Dis. 2016;16:847–56.
  39. Nathwani D, et al. Impact of antimicrobial stewardship interventions. J Antimicrob Chemother. 2019;74:13–21.
  40. Indian Council of Medical Research. Antimicrobial resistance surveillance report. New Delhi; 2022.
  41. National Centre for Disease Control. National programme on AMR containment. New Delhi; 2021.
  42. ICMR. Treatment guidelines for antimicrobial use in common syndromes. 2019.
  43. Ministry of Health and Family Welfare. Schedule H1 notification. Government of India; 2014.
  44. Government of India. National Action Plan on AMR 2017–2021.
  45. National Health Authority. Ayushman Bharat PMJAY guidelines. 2022.
  46. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10): e51–77.

Reference

  1. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
  2. WHO. Antimicrobial resistance global report. Geneva: WHO; 2023.
  3. O’Neill J. Review on antimicrobial resistance. London; 2016.
  4. CDC. Core elements of hospital antibiotic stewardship programs. Atlanta; 2019.
  5. ICMR. Antimicrobial resistance surveillance report. New Delhi; 2022.
  6. NCDC. National programme on AMR containment. Delhi; 2021.
  7. Government of India. National Action Plan on AMR 2017–2021.
  8. Laxminarayan R, et al. Antibiotic resistance in India. Lancet Infect Dis. 2013.
  9. Klein EY, et al. Global antibiotic consumption. PNAS. 2018.
  10. Davey P, et al. Interventions to improve antibiotic prescribing. Cochrane Database. 2017.
  11. Dyar OJ, et al. What is antimicrobial stewardship? Clin Microbiol Infect. 2017.
  12. Dellit TH, et al. IDSA guidelines for ASP. Clin Infect Dis. 2007.
  13. Barlam TF, et al. Implementing ASP. Clin Infect Dis. 2016.
  14. Pulcini C, et al. Role of pharmacists in stewardship. Int J Antimicrobe Agents. 2014.
  15. MacDougall C, Polk RE. Stewardship programs. Clin Microbiol Rev. 2005.
  16. Schuts EC, et al. Current evidence for ASP. Lancet Infect Dis. 2016.
  17. Nathwani D, et al. Impact of stewardship. J Antimicrob Chemother. 2019.
  18. WHO. GLASS report. Geneva; 2022.
  19. Tamma PD, et al. Stewardship strategies. Clin Infect Dis. 2014.
  20. Dik JW, et al. Measuring antibiotic use. Lancet Infect Dis. 2016.
  21. Charani E, et al. Behavioral change in stewardship. Clin Infect Dis. 2013.
  22. ICMR. Treatment guidelines for antimicrobial use. 2019.
  23. Ministry of Health India. Schedule H1 notification. 2014.
  24. Kotwani A, et al. Antibiotic use in India. BMJ Glob Health. 2019.
  25. Chandy SJ, et al. Community antibiotic use. Indian J Med Res. 2013.
  26. WHO. Antimicrobial stewardship programmes in healthcare facilities. 2019.
  27. CDC. Antibiotic resistance threats report. 2019.
  28. Nair M, et al. Hospital antibiotic policy India. J Clin Diagn Res. 2017.
  29. Singh S, et al. ASP implementation India. Indian J Pharm Pract. 2020.
  30. Ayushman Bharat PMJAY guidelines. Govt of India. 2022.
  31. OECD. Stemming the superbug tide. 2018.
  32. Holmes AH, et al. Understanding drivers of AMR. Lancet. 2016.
  33. Llor C, Bjerrum L. Antimicrobial prescribing. Clin Microbiol Infect. 2014.
  34. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO; 2015.
  35. World Health Organization. Antimicrobial resistance global report. Geneva: WHO; 2023.
  36. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London; 2016.
  37. Holmes AH, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387:176–87.
  38. Schuts EC, et al. Current evidence on hospital antimicrobial stewardship objectives. Lancet Infect Dis. 2016;16:847–56.
  39. Nathwani D, et al. Impact of antimicrobial stewardship interventions. J Antimicrob Chemother. 2019;74:13–21.
  40. Indian Council of Medical Research. Antimicrobial resistance surveillance report. New Delhi; 2022.
  41. National Centre for Disease Control. National programme on AMR containment. New Delhi; 2021.
  42. ICMR. Treatment guidelines for antimicrobial use in common syndromes. 2019.
  43. Ministry of Health and Family Welfare. Schedule H1 notification. Government of India; 2014.
  44. Government of India. National Action Plan on AMR 2017–2021.
  45. National Health Authority. Ayushman Bharat PMJAY guidelines. 2022.
  46. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10): e51–77.

Photo
Srushti kadam
Corresponding author

Department Of Pharmacy Practice, Shivlingeshwar College Of Pharmacy Almala, Dist. Latur-413512

Photo
Sanika Kadam
Co-author

Department Of Pharmacy Practice, Shivlingeshwar College Of Pharmacy Almala, Dist. Latur-413512

Photo
Dr. Ashok Giri
Co-author

Department Of Pharmacy Practice, Shivlingeshwar College Of Pharmacy Almala, Dist. Latur-413512

Srushti kadam, Sanika Kadam, Dr. Ashok Giri, Clinical Pharmacist-Led Antibiotic Stewardship Programs: A Key Strategy for Healthy India-A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 1777-1784, https://doi.org/10.5281/zenodo.19507000

More related articles
Formulation and Evaluation of Anti-Aging Serum usi...
Swapnil Pradhan, Snehalta Mali, Gauri Bhamare, Raj Patil, Neha Pa...
Niosomal Drug Delivery Systems: Emerging Trends in...
Imran Rashid, Quazia Ifaq Wani, Arashjit Singh, Neha Srivastava...
Groundnut Shell-Derived Activated Carbon for Lead (Ii) Removal from Aqueous Solu...
Stuti Ganbote, Yogesh Kolekar , Omkar Dhanawade, Pranavi Yadav, Siya Desai , Shravani Kumbhar, Prano...
The Comparision Between Rosuvastatin And Atorvastatin On Lipid Profile, Predispo...
Rudhra Sandhya, P. S. V. Sandeep, Deepika Pallati, Dr. Swathi Boddupally, Dr. Haritha. P, Mohd Shahn...
Related Articles
Antibody-Drug Conjugates in Modern Prodrug Design: Linker Chemistry and Payload ...
G. E. Ebimo-Moko, T. Ganatra, V. Ebimo-Moko, W. E. Madu, J. E. Sampson, J. D. Joel, F. O. Oladele...
Natural Hand Hygiene Solutions: A Review of Areca Catechu Leaf Sheath-Based Herb...
Aishwarya M, Dr. Shiju L, Bhoomika C K, Thejaswi Gowda K M, Sachin. M S, Harsha C J...
Formulation and Evaluation of Anti-Aging Serum using Ferulic Acid from Matsyaksh...
Swapnil Pradhan, Snehalta Mali, Gauri Bhamare, Raj Patil, Neha Patil, Kalyani Patil...
More related articles
Formulation and Evaluation of Anti-Aging Serum using Ferulic Acid from Matsyaksh...
Swapnil Pradhan, Snehalta Mali, Gauri Bhamare, Raj Patil, Neha Patil, Kalyani Patil...
Niosomal Drug Delivery Systems: Emerging Trends in Dermatological Applications...
Imran Rashid, Quazia Ifaq Wani, Arashjit Singh, Neha Srivastava...
Formulation and Evaluation of Anti-Aging Serum using Ferulic Acid from Matsyaksh...
Swapnil Pradhan, Snehalta Mali, Gauri Bhamare, Raj Patil, Neha Patil, Kalyani Patil...
Niosomal Drug Delivery Systems: Emerging Trends in Dermatological Applications...
Imran Rashid, Quazia Ifaq Wani, Arashjit Singh, Neha Srivastava...